caa a22 4500 605491216 CHVBK 20210128100509.0 cr unu---uuuuu 210128e20150801xx s 000 0 eng 10.1007/s10147-014-0759-2 doi (NATIONALLICENCE)springer-10.1007/s10147-014-0759-2 Prognostic implications of receptor discordance between primary and recurrent breast cancer [Elektronische Daten] [Akiko Matsumoto, Hiromitsu Jinno, Takeshi Murata, Tomoko Seki, Maiko Takahashi, Tetsu Hayashida, Kaori Kameyama, Yuko Kitagawa] Background: Discordance rates of hormone receptor (HR) and human epidermal growth factor-2 (HER2) status between primary and recurrent breast cancer were reported to be in the wide range of 10-40%, although its prognostic relevance remains to be elucidated. Methods: Fifty-five breast cancer patients had biopsies or resections of recurrent lesions. Pathological assessments of the HR and HER2 status of primary and recurrent lesions were performed in a single laboratory at Keio University Hospital. Tumors were classified as luminal (HR+ and HER2−), luminal/HER2 (HR+ and HER2+), HER2 (HR− and HER2+), or triple negative (HR− and HER2−). Results: Discordance rates in estrogen receptor (ER), progesterone receptor (PgR) and HER2 status between primary tumors and recurrent lesions were 16.4, 30.9 and 10.2%, respectively. Overall, 14 patients (25.5%) changed subtypes at recurrent lesions. Patients with a gain in ER and PgR status had a significantly longer disease-free interval compared with the corresponding concordant-negative patients (ER: 99.0 vs. 18.5months, p=0.037, PgR: 141.0 vs. 24.4months, p=0.011). Patients with a loss of HER2 status experienced a trend toward shorter time to progression, compared with patients who maintained HER2 positivity (4.0 vs. 18.4months, p=0.051). Conclusions: Discordance in receptor status between primary and recurrent breast cancers were seen in 10-30%. A gain in HR status was significantly associated with better prognosis. Japan Society of Clinical Oncology, 2014 Breast cancer nationallicence Receptor nationallicence Discordance nationallicence Recurrence nationallicence Prognosis nationallicence Biopsy nationallicence Matsumoto Akiko Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, 160-8582, Tokyo, Japan aut Jinno Hiromitsu Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, 160-8582, Tokyo, Japan aut Murata Takeshi Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, 160-8582, Tokyo, Japan aut Seki Tomoko Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, 160-8582, Tokyo, Japan aut Takahashi Maiko Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, 160-8582, Tokyo, Japan aut Hayashida Tetsu Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, 160-8582, Tokyo, Japan aut Kameyama Kaori Division of Pathological Diagnosis, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, 160-8582, Tokyo, Japan aut Kitagawa Yuko Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, 160-8582, Tokyo, Japan aut International Journal of Clinical Oncology Springer Japan 20/4(2015-08-01), 701-708 1341-9625 20:4<701 2015 20 10147 https://doi.org/10.1007/s10147-014-0759-2 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10147-014-0759-2 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Matsumoto Akiko Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, 160-8582, Tokyo, Japan aut NATIONALLICENCE 700 1- Jinno Hiromitsu Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, 160-8582, Tokyo, Japan aut NATIONALLICENCE 700 1- Murata Takeshi Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, 160-8582, Tokyo, Japan aut NATIONALLICENCE 700 1- Seki Tomoko Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, 160-8582, Tokyo, Japan aut NATIONALLICENCE 700 1- Takahashi Maiko Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, 160-8582, Tokyo, Japan aut NATIONALLICENCE 700 1- Hayashida Tetsu Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, 160-8582, Tokyo, Japan aut NATIONALLICENCE 700 1- Kameyama Kaori Division of Pathological Diagnosis, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, 160-8582, Tokyo, Japan aut NATIONALLICENCE 700 1- Kitagawa Yuko Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, 160-8582, Tokyo, Japan aut NATIONALLICENCE 773 0- International Journal of Clinical Oncology Springer Japan 20/4(2015-08-01), 701-708 1341-9625 20:4<701 2015 20 10147